
    
      The primary objectives of this phase I/II study are to identify the most appropriate dose of
      Carfilzomib in combination with a standard MP treatment regimen (phase I) and to evaluate the
      efficacy of Carfilzomib plus MP (CMP) in terms of overall response rate [(ORR), consisting of
      complete response (CR), very good partial response (VGPR), and partial response (PR) (phase
      II)]. Phase I/II single arm open label
    
  